𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Rotigotine transdermal patch in early Parkinson's disease: A randomized, double-blind, controlled study versus placebo and ropinirole

✍ Scribed by Nir Giladi; Babak Boroojerdi; Amos D. Korczyn; David J. Burn; Carl E. Clarke; Anthony H.V. Schapira

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
167 KB
Volume
22
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Rotigotine is a new, non‐ergot dopamine agonist formulated in a transdermal delivery system. The present study was to investigate the efficacy and safety of the rotigotine transdermal patch in the treatment of early Parkinson's disease. Patients (n = 561) were randomized to rotigotine, ropinirole, or placebo. The titration period was up to 13 weeks, and there was a minimum dose‐maintenance period of 24 weeks for ropinirole and 33 weeks for rotigotine. The primary endpoint was the proportion of patients with a minimum of 20% decrease in the combined Unified Parkinson's Disease Rating Scale Part II and Part III scores. The responder rate in the rotigotine group was significantly higher than in the placebo group (52% vs. 30%, P < 0.0001). Transdermal rotigotine at doses ≤8 mg/24 h did not show noninferiority to ropinirole at doses ≤24 mg/day. In a post‐hoc subgroup analysis, rotigotine ≤8 mg/24 hours had a similar efficacy to ropinirole at doses ≤12 mg/day. The rotigotine transdermal patch was well tolerated. The most common adverse events were application‐site reactions, nausea, and somnolence. Application‐site reactions were predominantly mild or moderate in intensity. In conclusion, the rotigotine transdermal patch represents an effective and safe option for the treatment of patients with early Parkinson's disease.

📜 SIMILAR VOLUMES

A six-month double-blind, randomized, pl
A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patch versus capsule
✍ Bengt Winblad; Jeffrey Cummings; Niels Andreasen; George Grossberg; Marco Onofrj 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 231 KB

## Abstract ## Objectives To compare the efficacy, safety and tolerability of a novel rivastigmine transdermal patch with conventional rivastigmine capsules and placebo in patients with Alzheimer's disease (AD). ## Methods In this 24‐week, multicenter, double‐blind, double‐dummy, placebo‐ and ac

Botulinum toxin type A for drooling in P
Botulinum toxin type A for drooling in Parkinson's disease: A double-blind, randomized, placebo-controlled study
✍ Giovanni Lagalla; Marzia Millevolte; Marianna Capecci; Leandro Provinciali; Mari 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

To investigate the safety and efficacy of botulinum toxin type A (BoNTX) treatment to reduce sialorrhea in Parkinson's disease (PD), a double-blind, randomized, placebo-controlled study enrolled 32 PD patients complaining of excessive drooling. Patients received either 50 U Botox in each parotid gla

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients
✍ Fabrizio Stocchi; Rupam Borgohain; Marco Onofrj; Anthony H.V. Schapira; Mohit Bh 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 446 KB 👁 2 views

## Abstract Safinamide is an α‐aminoamide with both dopaminergic and nondopaminergic mechanisms of action evaluated as an add‐on to dopamine agonist (DA) therapy in early‐stage PD. In this 24‐week, double‐blind study, patients with early PD receiving a stable dose of a single DA were randomized to

Comparison of desipramine and citalopram
Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double-blind, randomized, placebo-controlled study
✍ David Devos; Kathy Dujardin; Isabelle Poirot; Caroline Moreau; Olivier Cottencin 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB 👁 2 views

## Abstract Depression is one of the most common psychiatric disturbances in Parkinson's disease (PD). Recent reviews have highlighted the lack of controlled trials and the ensuing difficulty in formulating recommendations for antidepressant use in PD. We sought to establish whether antidepressants

Randomized, double-blind study of pramip
Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease
✍ Yoshikuni Mizuno; Nobuo Yanagisawa; Sadako Kuno; Mitsutoshi Yamamoto; Kazuko Has 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB

## Abstract We compared the efficacy and safety of pramipexole (PPX) with placebo in the treatment of advanced Parkinson's disease (PD) as an adjunct to levodopa. A bromocriptine (BR) group was included to enable determination of the noninferiority of PPX relative to BR as the standard treatment. ©